

*Clinical and Experimental Nephrology*

**Pharmacodynamics of Evocalcet for Secondary Hyperparathyroidism in Japanese Hemodialysis Patients**

Takashi Shigematsu, MD, PhD, Ryutaro Shimazaki, Masafumi Fukagawa, MD, PhD and Tadao Akizawa, MD, PhD,  
Evocalcet Study Group

**Correspondence to:**

Takashi Shigematsu

Department of Nephrology, Wakayama Medical University, 811-1 Kimiidera, Wakayama city, Wakayama, 641-8509,  
Japan

E-mail: [taki@wakayama-med.ac.jp](mailto:taki@wakayama-med.ac.jp)

## **Supplementary Text S2**

### *Escalation criteria*

The following escalation criteria had to be met for patients to transition to the next step: no serious adverse event that could be causally related to evocalcet, a corrected serum calcium level of  $\geq 7.5$  mg/dL at each time point, and patient safety was not judged to be of concern by the investigators. If any of the escalation criteria were not met, then the following transitions were performed at each step: Step 1 (study completion); Step 2 (escalation to Step 4, without proceeding to Step 5); Step 3 (escalation to Step 4, and allowed to proceed to Step 5 but not to Step 6); and Steps 4, 5, or 6 (study completion).